A TNF- α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation
In this study, we used lipopolysaccharide (LPS) to create a model of cognitive impairment by inducing systemic and neuroinflammation in experimental animals. LPS was injected intraperitoneally at a dose of 0.5mg/kg during the last seven days of the study. Adalimumab (ADA), a TNF-α inhibitor, was injected at a dose of 10mg/kg a total of 3 times throughout the study. On the last two days of the experiment, 50mg/kg of curcumin was administered orally as a positive control group. Open field (OF) and elevated plus maze tests (EPM) were used to measure anxiety-like behaviors. The tail suspension test (TST) was used to measure d...
Source: Behavioural Brain Research - April 10, 2024 Category: Neurology Authors: Mehmet Öz H üseyin Erdal Source Type: research
A TNF- α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation
In this study, we used lipopolysaccharide (LPS) to create a model of cognitive impairment by inducing systemic and neuroinflammation in experimental animals. LPS was injected intraperitoneally at a dose of 0.5mg/kg during the last seven days of the study. Adalimumab (ADA), a TNF-α inhibitor, was injected at a dose of 10mg/kg a total of 3 times throughout the study. On the last two days of the experiment, 50mg/kg of curcumin was administered orally as a positive control group. Open field (OF) and elevated plus maze tests (EPM) were used to measure anxiety-like behaviors. The tail suspension test (TST) was used to measure d...
Source: Brain Research - April 10, 2024 Category: Neurology Authors: Mehmet Öz H üseyin Erdal Source Type: research
Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum
Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.NO ABSTRACTPMID:38597123 | DOI:10.1111/ajd.14266 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Giorgia Salvia Matteo Bevilacqua Flavia Manzo Margiotta Alessandra Michelucci Giammarco Granieri Cristian Fidanzi Valentina Dini Marco Romanelli Carlo Mazzatenta Source Type: research
Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.PMID:38597096 | DOI:10.1111/ajd.14267 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Guiovana Fernanda Osorio-G ómez Juan Ortiz- Álvarez Delia Diaz-Ceca Cesar Guijarro-S ánchez Juli án Conejo-Mir Sánchez Pablo Fern ández Crehuet Source Type: research
Effect of adalimumab as an anti-inflammatory agent on gene expression of retinal pigment epithelial cells
In conclusion, despite its safety, the 2x concentration of ADA was the only dose that did not ignite the expression of any of the studied inflammatory and fibrogenesis genes. This dosage, which is roughly equal to 2 mg intravitreal dose in a clinical setting, might be referred to as a reference starting point for future in-vivo studies in ocular conditions.PMID:38599062 | DOI:10.1016/j.biopha.2024.116568 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 10, 2024 Category: Drugs & Pharmacology Authors: M Hossein Nowroozzadeh Mojtaba Yousefi Mostafa Abuali Fatemeh Sanie-Jahromi Source Type: research
A TNF- α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation
In this study, we used lipopolysaccharide (LPS) to create a model of cognitive impairment by inducing systemic and neuroinflammation in experimental animals. LPS was injected intraperitoneally at a dose of 0.5mg/kg during the last seven days of the study. Adalimumab (ADA), a TNF-α inhibitor, was injected at a dose of 10mg/kg a total of 3 times throughout the study. On the last two days of the experiment, 50mg/kg of curcumin was administered orally as a positive control group. Open field (OF) and elevated plus maze tests (EPM) were used to measure anxiety-like behaviors. The tail suspension test (TST) was used to measure d...
Source: Behavioural Brain Research - April 10, 2024 Category: Neurology Authors: Mehmet Öz H üseyin Erdal Source Type: research
A TNF- α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation
In this study, we used lipopolysaccharide (LPS) to create a model of cognitive impairment by inducing systemic and neuroinflammation in experimental animals. LPS was injected intraperitoneally at a dose of 0.5mg/kg during the last seven days of the study. Adalimumab (ADA), a TNF-α inhibitor, was injected at a dose of 10mg/kg a total of 3 times throughout the study. On the last two days of the experiment, 50mg/kg of curcumin was administered orally as a positive control group. Open field (OF) and elevated plus maze tests (EPM) were used to measure anxiety-like behaviors. The tail suspension test (TST) was used to measure d...
Source: Brain Research - April 10, 2024 Category: Neurology Authors: Mehmet Öz H üseyin Erdal Source Type: research
Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum
Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.NO ABSTRACTPMID:38597123 | DOI:10.1111/ajd.14266 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Giorgia Salvia Matteo Bevilacqua Flavia Manzo Margiotta Alessandra Michelucci Giammarco Granieri Cristian Fidanzi Valentina Dini Marco Romanelli Carlo Mazzatenta Source Type: research
Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.PMID:38597096 | DOI:10.1111/ajd.14267 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Guiovana Fernanda Osorio-G ómez Juan Ortiz- Álvarez Delia Diaz-Ceca Cesar Guijarro-S ánchez Juli án Conejo-Mir Sánchez Pablo Fern ández Crehuet Source Type: research
A TNF- α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation
In this study, we used lipopolysaccharide (LPS) to create a model of cognitive impairment by inducing systemic and neuroinflammation in experimental animals. LPS was injected intraperitoneally at a dose of 0.5mg/kg during the last seven days of the study. Adalimumab (ADA), a TNF-α inhibitor, was injected at a dose of 10mg/kg a total of 3 times throughout the study. On the last two days of the experiment, 50mg/kg of curcumin was administered orally as a positive control group. Open field (OF) and elevated plus maze tests (EPM) were used to measure anxiety-like behaviors. The tail suspension test (TST) was used to measure d...
Source: Behavioural Brain Research - April 10, 2024 Category: Neurology Authors: Mehmet Öz H üseyin Erdal Source Type: research
Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum
Australas J Dermatol. 2024 Apr 10. doi: 10.1111/ajd.14266. Online ahead of print.NO ABSTRACTPMID:38597123 | DOI:10.1111/ajd.14266 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Giorgia Salvia Matteo Bevilacqua Flavia Manzo Margiotta Alessandra Michelucci Giammarco Granieri Cristian Fidanzi Valentina Dini Marco Romanelli Carlo Mazzatenta Source Type: research
Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.PMID:38597096 | DOI:10.1111/ajd.14267 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Guiovana Fernanda Osorio-G ómez Juan Ortiz- Álvarez Delia Diaz-Ceca Cesar Guijarro-S ánchez Juli án Conejo-Mir Sánchez Pablo Fern ández Crehuet Source Type: research
Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - April 10, 2024 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Multiple sclerosis associated with adalimumab use in ankylosing spondylitis
(Source: Neurological Sciences)
Source: Neurological Sciences - April 10, 2024 Category: Neurology Source Type: research
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn ’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
ConclusionThe final prediction model seems promising to select patients who could successfully increase their ADA dose interval. The model should be validated externally before it may be applied in clinical practice.Clinical Trial Registration NumberClinicalTrials.gov, number NCT03172377. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - April 9, 2024 Category: Gastroenterology Source Type: research
